IDH2 and cholangiocarcinoma: Recently, positive phase III data for CCA patients harboring IDH mutations were reported for the IDH inhibitor ivosidenib, emphasizing the direct relevance of such preclinical platforms for “co-clinical trials” to establish mechanisms and biomarkers of response and resistance to the molecularly targeted inhibitors.